Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma — Stella
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
United States
Children's Hospital of Alabama, Birmingham, Alabama
Children's Hospital Los Angeles, Los Angeles, California
Children's Hospital of Orange County, Orange, California
Children's Hospital Colorado, Aurora, Colorado
Children's National Medical Center, Washington D.C., District of Columbia
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia